V.A. Cure is a European MSCA-ITN network aiming to uncover core mechanisms of initiation and maintenance of Vascular Anomalies (VAs) and to leverage this information for establishing novel therapeutic strategies. The network consortium consists of 7 academic laboratories and 2 companies from across Europe, and is supported by 9 partner organisations.
The 14 Early Stage Researchers (ESRs) will be a part of the unique international PhD program, consisting of an individual research project, the network’s training programme, intersectoral secondments and outreach activities. Project goal is to ensure a comprehensive perception of the research and drug/technology development in pharma industry/biotech and academia.
Finnadvance’s got funded for blood vessel-on-a-chip which could be used to treat rare vascular diseases! Organ- or body-on-chips both speed up the process and improve the safety and patient outcomes. Futuristic, but this can be a reality in 3-5 years! Official press release Finnadvance completes 550k€ seed round led by Voima Ventures and Finnish biotech
14 students, 10 supervisors and 4 partner organisations participated on the 3 day extensive networking, training and workshops of the V.A.Cure project held from 13-15th of November in de Duve Institute in Brussels.
Diversity and environment that fosters equal opportunities in research are very important aspects of our project. Through inclusion of diversity, we grow professionally and personally.Early stage researchers of V.A.Cure project are coming from all over the world: Singapore, Iran, Vietnam, Turkey, Italy, Germany, Slovenia, Lebanon, Austria, Spain and USA.